IL6 and COVID-19: In addition, we had no information on the stage of cancer or on the treatments, whether anti-cancer treatments (which would have allowed us to evaluate the potentially induced immuno-suppression) such as hormonal therapy, or other treatments used in other pathologies, which may influence (for good or bad) the severity of COVID-19 in hospitalized patients, such as different inhibitors (tyrosine kinase, IL6, ARA2).